持续罗哌卡因切口浸润与硬膜外吗啡在非计划剖宫产术后的非劣效性随机对照研究
主要结局为术后24小时活动时VAS疼痛评分,罗哌卡因组为4.4(95%CI 3.6-5.1),吗啡组为3.1(95%CI 2.4-3.9),两组差值1.2(95%CI 0.2-2.3)超过预设非劣效界值1,未能证明非劣效。罗哌卡因组补救吗啡使用更频繁、满意度更低,但吗啡相关副作用更少;18%患者持续切口浸润技术不可行。
要点
- 持续罗哌卡因切口浸润在非计划剖宫产术后镇痛未达到非劣效于硬膜外吗啡。
- 罗哌卡因组24小时活动时VAS评分更高,补救吗啡使用更频繁且满意度更低。
- 18%患者持续切口浸润技术不可行,仅推荐用于神经轴吗啡禁忌时。
核心结论
- 未能证明持续罗哌卡因切口浸润在非计划剖宫产术后镇痛方面非劣效于硬膜外吗啡。
- 因技术失败率显著,持续切口浸润仅应在神经轴吗啡禁忌时考虑。
研究设计与样本
- 三盲、非劣效、随机对照试验,在一家大学医院于2015年2月至2021年8月进行。
主要发现
- 术后24小时活动时VAS疼痛评分:罗哌卡因组4.4(95%CI 3.6-5.1),吗啡组3.1(95%CI 2.4-3.9)。
- 两组平均VAS疼痛差值1.2(95%CI 0.2-2.3),超过预设非劣效界值1。
- 两组在6小时和24小时静息及活动时差异均具有统计学显著性。
- 罗哌卡因组补救吗啡使用更频繁,满意度更低,但吗啡相关副作用更少。
- 18%患者持续切口浸润技术不可行。
关键数值与推荐
- 非劣效界值预设为VAS疼痛评分差值1。
- 主要结局为术后24小时活动时VAS疼痛评分(0-10),评估者不知分组。
临床怎么用
- 持续罗哌卡因切口浸润不应作为非计划剖宫产术后常规镇痛替代硬膜外吗啡。
- 仅在神经轴吗啡禁忌时考虑持续切口浸润,并需告知技术失败可能。
局限性
- 18%患者持续切口浸润技术不可行,可能影响实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment programs designed to enhance recovery after caesarean delivery include multimodal analgesia to ensure optimal analgesia while reducing exposure to systemic opioids. Evidence for the effectiveness of continuous wound infiltration with local anaesthetic after unplanned caesarean delivery is needed. OBJECTIVE: To determine whether continuous ropivacaine wound infiltration has noninferior analgesic properties compared to epidural morphine, while reducing side effects related to opioids. DESIGN: Triple-blinded, noninferiority, randomised controlled trial. SETTING: One university hospital, between February 2015 and August 2021. PATIENTS: Eighty-one women undergoing unplanned lower segment caesarean section under epidural anaesthesia. INTERVENTION: At the end of the procedure, randomly assigned patients received either an epidural bolus of 0.9% saline with 48 h continuous ropivacaine wound infusion (ropivacaine group) or an epidural bolus of morphine with 48 h 0.9% saline wound infusion (morphine group). MAIN OUTCOME MEASURES: Pain during mobilisation at 24 h postsurgery was assessed using the visual analogue pain scale (VAS 0 to 10) with no indication of the allocated group. RESULTS: Pain scores were 4.4 (95% CI, 3.6 to 5.1) in the ropivacaine group versus 3.1 (95% CI, 2.4 to 3.9) in the morphine group. The mean VAS pain difference between the two groups was 1.2 (95% CI, 0.2 to 2.3), which exceeded the prespecified noninferiority margin of 1. The differences between the two groups at rest and during mobilisation at 6 and 24 h were statistically significant. The ropivacaine group received rescue morphine more frequently, and were less satisfied despite fewer morphine-related side effects. Continuous wound infiltration was not technically feasible in 18% of the patients. CONCLUSIONS: We failed to show that continuous ropivacaine wound infiltration was noninferior to epidural morphine in providing analgesia after unplanned caesarean delivery. Because of a significant rate of technical failures, continuous wound infiltration should only be considered when neuraxial morphine is contraindicated.
引用
- Bruillot M, Pieper A, Sourd D, et al. Continuous ropivacaine wound infiltration versus epidural morphine after unplanned caesarean delivery: A noninferiority randomised controlled study. Eur J Anaesthesiol. 2025. PMID: 39912531. doi:10.1097/EJA.0000000000002135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。